Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AGTINASDAQ:RLAYNASDAQ:SUPNNASDAQ:SWTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGTIAgiliti$10.06$5.07▼$18.61$1.37B1.91.78 million shs26.51 million shsRLAYRelay Therapeutics$3.11+3.7%$2.92$1.78▼$10.72$533.19M1.652.08 million shs2.04 million shsSUPNSupernus Pharmaceuticals$32.15+1.4%$31.86$25.53▼$40.28$1.80B0.74491,895 shs433,034 shsSWTXSpringWorks Therapeutics$46.12-0.3%$44.26$28.21▼$62.00$3.46B0.772.02 million shs8.42 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGTIAgiliti0.00%0.00%0.00%0.00%0.00%RLAYRelay Therapeutics+3.32%-6.33%+28.51%-16.84%-51.56%SUPNSupernus Pharmaceuticals+1.42%-0.74%+1.52%-16.82%+11.02%SWTXSpringWorks Therapeutics-0.30%-0.24%+26.46%-16.34%+12.79%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGTIAgilitiN/AN/AN/AN/AN/AN/AN/AN/ARLAYRelay Therapeutics3.0345 of 5 stars4.41.00.00.02.72.50.6SUPNSupernus Pharmaceuticals2.8738 of 5 stars2.23.00.04.12.70.80.0SWTXSpringWorks Therapeutics2.159 of 5 stars3.13.00.00.03.30.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGTIAgiliti 0.00N/AN/AN/ARLAYRelay Therapeutics 2.83Moderate Buy$17.67468.06% UpsideSUPNSupernus Pharmaceuticals 2.33Hold$36.0011.98% UpsideSWTXSpringWorks Therapeutics 2.13Hold$52.5713.99% UpsideCurrent Analyst Ratings BreakdownLatest AGTI, SUPN, SWTX, and RLAY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025SWTXSpringWorks TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$47.00 ➝ $47.005/7/2025RLAYRelay TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $10.004/30/2025SWTXSpringWorks TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$74.00 ➝ $47.004/29/2025SWTXSpringWorks TherapeuticsCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeHold4/29/2025SWTXSpringWorks TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$66.00 ➝ $47.004/28/2025SWTXSpringWorks TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$77.00 ➝ $47.004/28/2025SWTXSpringWorks TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/28/2025SWTXSpringWorks TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$63.00 ➝ $47.004/28/2025SWTXSpringWorks TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$81.00 ➝ $47.004/17/2025RLAYRelay TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageEqual Weight$4.003/7/2025RLAYRelay TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGTIAgiliti$1.17B0.00N/A5.76$6.98 per share0.00RLAYRelay Therapeutics$7.68M69.44N/AN/A$5.90 per share0.53SUPNSupernus Pharmaceuticals$668.00M2.69$1.47 per share21.83$16.87 per share1.91SWTXSpringWorks Therapeutics$191.59M18.05N/AN/A$10.01 per share4.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGTIAgiliti-$19.42M-$0.14N/A0.00N/A-1.65%6.47%2.53%N/ARLAYRelay Therapeutics-$341.97M-$2.23N/AN/AN/AN/A-45.75%-40.75%N/ASUPNSupernus Pharmaceuticals$1.32M$1.1130.0522.33N/A9.16%7.79%5.67%5/14/2025 (Estimated)SWTXSpringWorks Therapeutics-$325.10M-$3.48N/AN/AN/A-134.73%-46.74%-41.12%N/ALatest AGTI, SUPN, SWTX, and RLAY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025SUPNSupernus Pharmaceuticals$0.37N/AN/AN/AN/AN/A5/9/2025Q1 2025SWTXSpringWorks Therapeutics-$0.81-$1.11-$0.30-$1.11$64.19 million$49.09 million5/5/2025Q1 2025RLAYRelay Therapeutics-$0.50-$0.46+$0.04-$0.46$0.01 million$7.68 million2/26/2025Q4 2024RLAYRelay Therapeutics-$0.57-$0.45+$0.12-$0.45$5.53 millionN/A2/20/2025Q4 2024SWTXSpringWorks Therapeutics-$0.66-$1.04-$0.38-$1.04$60.53 million$61.55 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGTIAgilitiN/AN/AN/AN/AN/ARLAYRelay TherapeuticsN/AN/AN/AN/AN/ASUPNSupernus PharmaceuticalsN/AN/AN/AN/AN/ASWTXSpringWorks TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGTIAgiliti1.131.721.34RLAYRelay TherapeuticsN/A18.4218.42SUPNSupernus PharmaceuticalsN/A2.201.98SWTXSpringWorks TherapeuticsN/A6.166.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGTIAgiliti99.12%RLAYRelay Therapeutics96.98%SUPNSupernus PharmaceuticalsN/ASWTXSpringWorks TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipAGTIAgiliti4.16%RLAYRelay Therapeutics4.87%SUPNSupernus Pharmaceuticals9.30%SWTXSpringWorks Therapeutics7.83%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGTIAgiliti5,800136.08 million130.42 millionOptionableRLAYRelay Therapeutics330171.45 million160.15 millionOptionableSUPNSupernus Pharmaceuticals58055.99 million50.08 millionOptionableSWTXSpringWorks Therapeutics23074.98 million68.73 millionOptionableAGTI, SUPN, SWTX, and RLAY HeadlinesRecent News About These CompaniesSpringWorks Therapeutics (NASDAQ:SWTX) Given Neutral Rating at GuggenheimMay 13 at 2:25 AM | americanbankingnews.comAlgert Global LLC Takes Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)May 12 at 4:15 AM | marketbeat.comSpringWorks Therapeutics (SWTX) Reports Q1 Loss, Misses Revenue EstimatesMay 9, 2025 | zacks.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) is Deep Track Capital LP's 6th Largest PositionMay 9, 2025 | marketbeat.comDuquesne Family Office LLC Acquires 154,628 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)May 9, 2025 | marketbeat.comDimensional Fund Advisors LP Lowers Stock Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)May 9, 2025 | marketbeat.comThe Manufacturers Life Insurance Company Has $14.73 Million Stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)May 6, 2025 | marketbeat.comArrowMark Colorado Holdings LLC Acquires 7,072 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)May 5, 2025 | marketbeat.comAlly Bridge Group NY LLC Has $1.98 Million Stock Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)May 4, 2025 | marketbeat.comBoxer Capital Management LLC Acquires New Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)May 4, 2025 | marketbeat.comSpringWorks Therapeutics' (SWTX) Neutral Rating Reaffirmed at HC WainwrightMay 3, 2025 | americanbankingnews.comSpringWorks Therapeutics' (SWTX) "Neutral" Rating Reiterated at HC WainwrightMay 2, 2025 | marketbeat.comEvercore ISI Downgrades SpringWorks Therapeutics (NASDAQ:SWTX) to HoldMay 2, 2025 | marketbeat.comPromising Growth Stocks To Follow Today - April 29thMay 1, 2025 | marketbeat.comBiotech Stocks To Follow Now - April 29thMay 1, 2025 | marketbeat.comSpringWorks Therapeutics' (SWTX) "Hold" Rating Reiterated at TD CowenMay 1, 2025 | marketbeat.comSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Stock Position Raised by Soros Fund Management LLCMay 1, 2025 | marketbeat.comHC Wainwright & Co. Downgrades SpringWorks Therapeutics (SWTX)May 1, 2025 | msn.comPromising Value Stocks To Watch Now - April 28thApril 30, 2025 | marketbeat.comTop Mid Cap Stocks Worth Watching - April 28thApril 30, 2025 | marketbeat.comBest Pharmaceutical Stocks To Watch Now - April 28thApril 30, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAGTI, SUPN, SWTX, and RLAY Company DescriptionsAgiliti NYSE:AGTIAgiliti, Inc., together with its subsidiaries, provides healthcare technology management and service solutions to the healthcare industry in the United States. The company offers onsite managed services that are comprehensive programs for the management, reprocessing, and logistics of medical equipment at individual facilities and integrated delivery networks to monitor and adjust equipment quantities and availability to address fluctuations in patient census and acuity. It also provides clinical engineering services comprising maintenance, repair, and remediation solutions for various types of medical equipment, including general biomedical equipment, diagnostic imaging equipment, and surgical equipment through supplemental and outsourced offerings. In addition, the company offers equipment solutions, which primarily provide supplemental, peak need, and per-case rental of general biomedical, specialty, and surgical equipment to acute care hospitals and alternate site providers, including premier healthcare institutions and integrated delivery networks. It serves acute care hospitals, health systems and integrated delivery networks and alternate site providers. The company was founded in 1939 and is headquartered in Eden Prairie, Minnesota. Agiliti, Inc. operates as a subsidiary of THL Agiliti LLC.Relay Therapeutics NASDAQ:RLAY$3.11 +0.11 (+3.67%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$3.20 +0.09 (+2.77%) As of 05/12/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Supernus Pharmaceuticals NASDAQ:SUPN$32.15 +0.45 (+1.42%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$32.40 +0.25 (+0.78%) As of 04:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.SpringWorks Therapeutics NASDAQ:SWTX$46.12 -0.14 (-0.30%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$46.11 -0.01 (-0.02%) As of 04:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
